Merck details Keytruda’s postsurgery lung cancer win, teeing up fight against Roche’s Tecentriq HIMSS 2022: Samsung rolls out smart healthcare TV, digital health tools for hospitals AstraZeneca throws open doors to new ideas in global postdoc challenge Medtronic shuffles surgical robotics, diabetes and cardiac business leaders Eiger eager to send COVID-19 drug to FDA after hospitalizations, deaths slashed—including against omicron Alnylam sues Pfizer and Moderna claiming infringement on its delivery technology for COVID shots HIMSS 2022: To retain staff, health systems need more insight into workers' needs and career goals AI-driven Deepcell raises $73M to further single-cell imaging tech NIH squashes Synairgen’s COVID therapy from ACTIV-2 trial after omicron shakes up study Moody's: Shift away from inpatient care will continue to shrink hospital margins GlaxoSmithKline wraps up Shingrix recall after inspection flagged cracked vials Invitae launches personalized cancer blood tests to spot tumor relapses Featured Story | By Angus Liu Merck has laid out the detailed data for Keytruda in adjuvant non-small cell lung cancer, with subgroup analyses showing a potential edge over Roche's first-to-market Tecentriq. read more |
| |
|---|
|
Top Stories By Heather Landi Electronics giant Samsung has been expanding its reach in healthcare with mobile devices and hardware for hospitals, home health and remote patient monitoring. The company is looking to leverage its tech expertise to improve in-room patient care. read more By Nick Paul Taylor AstraZeneca is throwing open its doors to ideas from scientists near the start of their careers. Through its global R&D Postdoctoral Challenge, the Anglo-Swedish drugmaker will equip researchers to pursue novel approaches to treating diseases. read more By Andrea Park It’s time for spring cleaning, and first on Medtronic’s to-do list is the reorganization of several of its field-specific medical device segments. read more By Kyle LaHucik Eiger BioPharmaceuticals' drug, licensed from Bristol Myers Squibb in 2016, halved the risk of hospitalizations or emergency room visits lasting longer than six hours in patients with COVID-19, including those with the omicron variant, in a phase 3 trial. read more By Kevin Dunleavy Alnylam has filed lawsuits claiming COVID-19 vaccine producers Moderna and Pfizer infringed on its patent for a delivery technology employed by both shots. The moves come after Arbutus and Genevant sued Moderna, claiming infringement on the same technology. read more By Dave Muoio ORLANDO, Florida—Amid a pandemic-fueled labor crisis, digital and analytics leaders encouraged organizations to invest more into understanding and meeting the needs of their existing employees. read more By Max Bayer AI and machine learning-based Deepcell has raised $73 million in series B funds to build out its whole-cell atlas and push towards commercialization. read more By Max Bayer The NIH has kiboshed Synairgen’s arm of the ACTIV-2 trial testing the company's SNG001 in nonhospitalized patients due to a “significant shift” in the pandemic (read: the omicron variant). The announcement from Synairgen Tuesday that recruitment was being halted came two weeks after the company first said the NIH had told it to slow its roll while the two tweaked the trial. read more By Anastassia Gliadkovskaya This shift will be partially offset by an aging population and demand for higher-acuity care by patients whose care was delayed by the pandemic. read more By Joseph Keenan GlaxoSmithKline recently closed out a voluntary recall of 130,500 doses of its market-leading shingles vaccine Shingrix after finding cracks in two vials. read more By Conor Hale The company’s Personalized Cancer Monitoring platform includes a set of assays that are tailored to a patient’s particular tumor. read more | 